Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Last updated July 6, 2022

Key Points

Key Points

Human epidermal growth factor receptor 2 (HER2)-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis.

Treatment

...Treatmen...

...First-Line...

....0Clinicians should recommend HER2-targeted therap...

...ommendation 1.1Clinicians should recomme...

...Seco...

...on 2.0If a patient’s HER2-positive advanced b...

...dation 2.1 (updated)If a patient’s HER2-...

...Third-...

...n 3.0If a patient’s HER2-positive advanced b...

...l, there are a lack of head-to-head trials, theref...

...ndation 3.1 (updated)If a patient’s HER2-po...

...ation 3.1.1 (updated)If a patient has not rece...

...3.1.2 (updated)May offer tucatinib combined with...

...mmendation 3.1.3 (updated)May offer trastuzu...

...ecommendation 3.1.4 (updated)May o...

...mendation 3.1.5May offer lapatinib...

Recommendation 3.1.6May offer lapatin...

...dation 3.1.7May offer other combinati...

...mendation 3.1.8 (updated)May offer ma...

...on 3.1.9If a patient has not received...

...commendation 3.2.0May offer hormonal therapy (...

...3.2.1 (updated)May offer abemaciclib...


...T...

...n 4.0If a patient is receiving HER2-t...


...Recurrence...

...mmendation 5.0If a patient finished tr...

...commendation 5.1If a patient finished trastuzu...


...First-Line...

...6.0If a patient’s cancer is hormone rece...

...6.0.1HER2-targeted therapy plus chemotherapy....

...dation 6.0.2Endocrine therapy plus trastu...

...6.0.3Endocrine therapy alone (in s...


Endocrine...

...mendation 7.0If the patient has started with a...


...First-Line Endoc...

...ommendation 8.0In special circumstances, such...


...re 1. Algorithm for Patients with HER...